erythropoiesis-stimulating agent

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

Adverse effects

Laboratory

Notes

More general terms

More specific terms

References

  1. Prescriber's Letter 17(4): 2010 ESA APPRISE Oncology Program for Cancer Patients Using Procrit, Epogen, or Aranesp COMMENTARY: ESA APPRISE Oncology Program for Cancer Patients Using Procrit, Epogen, or Aranesp CHART: Drugs with Special Prescribing and Dispensing Requirements Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260422&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. 2.0 2.1 Aspinall SL et al. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD. Am J Kidney Dis 2012 Sep; 60:371. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22633556
  3. 3.0 3.1 Swedberg K et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013 Mar 10 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23473338 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1214865
  4. 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18, 19. American College of Physicians, Philadelphia 2012, 2015, 2018, 2021.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  5. Solomon SD, Uno H, Lewis EF, Eckardt KU et al Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16;363(12):1146-55 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20843249
  6. Bohlius J, Schmidlin K, Brillant C et al Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009 May 2;373(9674):1532-42 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19410717
  7. 7.0 7.1 Locatelli F, Aljama P, Canaud B et al Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010 Sep;25(9):2846-50 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20591813
  8. 8.0 8.1 8.2 Tonia T, Mettler A, Robert N et al Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012 Dec 12;12:CD003407 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23235597
  9. 9.0 9.1 Collister D et al. The effect of erythropoietin-stimulating agents on health- related quality of life in anemia of chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 2016 Feb 16 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/2688184 <Internet> http://annals.org/article.aspx?articleid=2491918
  10. 10.0 10.1 Bohlius J, Bohlke K, Castelli R et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv 2019 Apr 23; 3:1197 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/30971397 Free PMC Article <Internet> http://www.bloodadvances.org/content/3/8/1197